USP37 deubiquitinates Cdt1 and contributes to regulate DNA replication
DNA replication control is a key process in maintaining genomic integrity. Monitoring DNA replication initiation is particularly important as it needs to be coordinated with other cellular events and should occur only once per cell cycle. Crucial players in the initiation of DNA replication are the ORC protein complex, marking the origin of replication, and the Cdt1 and Cdc6 proteins, that license these origins to replicate by recruiting the MCM2-7 helicase. To accurately achieve its functions, Cdt1 is tightly regulated. (Source: Molecular Oncology)
Source: Molecular Oncology - June 1, 2016 Category: Cancer & Oncology Authors: Santiago Hern ández-Pérez, Elisa Cabrera, Hugo Amoedo, Sara Rodríguez-Acebes, Stephane Koundrioukoff, Michelle Debatisse, Juan Méndez, Raimundo Freire Source Type: research
USP37 deubiquitinates Cdt1 and contributes to regulate DNA replication
DNA replication control is a key process in maintaining genomic integrity. Monitoring DNA replication initiation is particularly important as it needs to be coordinated with other cellular events and should occur only once per cell cycle. Crucial players in the initiation of DNA replication are the ORC protein complex, marking the origin of replication, and the Cdt1 and Cdc6 proteins, that licence these origins to replicate by recruiting the MCM2-7 helicase. To accurately achieve its functions, Cdt1 is tightly regulated. (Source: Molecular Oncology)
Source: Molecular Oncology - June 1, 2016 Category: Cancer & Oncology Authors: Santiago Hernández-Pérez, Elisa Cabrera, Hugo Amoedo, Sara Rodríguez-Acebes, Stephane Koundrioukoff, Michelle Debatisse, Juan Méndez, Raimundo Freire Source Type: research
Editorial Board
(Source: Molecular Oncology)
Source: Molecular Oncology - May 31, 2016 Category: Cancer & Oncology Source Type: research
Global re-wiring of p53 transcription regulation by the hepatitis B virus X protein
The tumour suppressor p53 is a central player in transcription regulation and cell fate determination. By interacting with p53 and altering its sequence-specific binding to the response elements, the hepatitis B virus X protein (HBx) was reported to re-direct p53 regulation of some genes. (Source: Molecular Oncology)
Source: Molecular Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Cheryl Chan, Thomas Thurnherr, Jingbo Wang, Xavier Gallart-Palau, Siu Kwan Sze, Steve Rozen, Caroline G. Lee Source Type: research
Editorial Board
(Source: Molecular Oncology)
Source: Molecular Oncology - May 31, 2016 Category: Cancer & Oncology Source Type: research
Global re-wiring of p53 transcription regulation by the hepatitis B virus X protein
The tumour suppressor p53 is a central player in transcription regulation and cell fate determination. By interacting with p53 and altering its sequence-specific binding to the response elements, the hepatitis B virus X protein (HBx) was reported to re-direct p53 regulation of some genes. (Source: Molecular Oncology)
Source: Molecular Oncology - May 31, 2016 Category: Cancer & Oncology Authors: Cheryl Chan, Thomas Thurnherr, Jingbo Wang, Xavier Gallart-Palau, Siu Kwan Sze, Steve Rozen, Caroline G. Lee Source Type: research
RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4
Pancreatic adenocarcinoma patients have low survival rates due to late-stage diagnosis and high rates of cancer recurrence even after surgical resection. It is important to understand the molecular characteristics associated with survival differences in pancreatic adenocarcinoma tumors that may inform patient care. (Source: Molecular Oncology)
Source: Molecular Oncology - May 26, 2016 Category: Cancer & Oncology Authors: Marie K. Kirby, Ryne C. Ramaker, Jason Gertz, Nicholas S. Davis, Bobbi E. Johnston, Patsy G. Oliver, Katherine C. Sexton, Edward W. Greeno, John D. Christein, Martin J. Heslin, James A. Posey, William E. Grizzle, Selwyn M. Vickers, Donald J. Buchsbaum, Sa Source Type: research
Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients
Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma patients. (Source: Molecular Oncology)
Source: Molecular Oncology - May 24, 2016 Category: Cancer & Oncology Authors: Thomas Urup, Signe Regner Michaelsen, Lars R ønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen, Ulrik Lassen Source Type: research
Angiotensinogen and HLA Class II Predict Bevacizumab Response in Recurrent Glioblastoma Patients
Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevacizumab response in recurrent glioblastoma patients. (Source: Molecular Oncology)
Source: Molecular Oncology - May 24, 2016 Category: Cancer & Oncology Authors: Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen, Ulrik Lassen Source Type: research
SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment – An in vitro evaluation
Treatment of unresectable primary cancer and their distant metastases, with the liver representing one of the most frequent location, is still plagued by insufficient treatment success and poor survival rates. The Sigma-2 receptor is preferentially expressed on many tumor cells making it an appealing target for therapy. Thus, we developed a potential targeted drug conjugate consisting of the Sigma-2 receptor ligand SW43 and Doxorubicin (SW43-DOX) for systemic cancer therapy and for locoregional treatment of primary and secondary liver malignancies when loaded onto drug-eluting bead (DEB) which was compared in vitro to th...
Source: Molecular Oncology - May 20, 2016 Category: Cancer & Oncology Authors: Johannes M. Ludwig, Yongkang Gai, Lingyi Sun, Guangya Xiang, Dexing Zeng, Hyun S. Kim Source Type: research
SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment – An in vitro evaluation
Treatment of unresectable primary cancer and their distant metastases, with the liver representing one of the most frequent location, is still plagued by insufficient treatment success and poor survival rates. The Sigma-2 receptor is preferentially expressed on many tumor cells making it an appealing target for therapy. Thus, we developed a potential targeted drug conjugate consisting of the Sigma-2 receptor ligand SW43 and Doxorubicin (SW43-DOX) for systemic cancer therapy and for locoregional treatment of primary and secondary liver malignancies when loaded onto drug-eluting bead (DEB) which was compared in vitro to th...
Source: Molecular Oncology - May 20, 2016 Category: Cancer & Oncology Authors: Johannes M. Ludwig, Yongkang Gai, Lingyi Sun, Guangya Xiang, Dexing Zeng, Hyun S. Kim Source Type: research
SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment – An in vitro evaluation
Treatment of unresectable primary cancer and their distant metastases, with the liver representing one of the most frequent location, is still plagued by insufficient treatment success and poor survival rates. The Sigma-2 receptor is preferentially expressed on many tumor cells making it an appealing target for therapy. Thus, we developed a potential targeted drug conjugate consisting of the Sigma-2 receptor ligand SW43 and Doxorubicin (SW43-DOX) for systemic cancer therapy and for locoregional treatment of primary and secondary liver malignancies when loaded onto drug-eluting bead (DEB) which was compared in vitro to the...
Source: Molecular Oncology - May 20, 2016 Category: Cancer & Oncology Authors: Johannes M. Ludwig, Yongkang Gai, Lingyi Sun, Guangya Xiang, Dexing Zeng, Hyun S. Kim Source Type: research
SW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluation
Treatment of unresectable primary cancer and their distant metastases, with the liver representing one of the most frequent location, is still plagued by insufficient treatment success and poor survival rates. The Sigma-2 receptor is preferentially expressed on many tumor cells making it an appealing target for therapy. Thus, we developed a potential targeted drug conjugate consisting of the Sigma-2 receptor ligand SW43 and Doxorubicin (SW43-DOX) for systemic cancer therapy and for locoregional treatment of primary and secondary liver malignancies when loaded onto drug-eluting bead (DEB) which was compared in vitro to the ...
Source: Molecular Oncology - May 20, 2016 Category: Cancer & Oncology Authors: Johannes M. Ludwig, Yongkang Gai, Lingyi Sun, Guangya Xiang, Dexing Zeng, Hyun S. Kim Source Type: research
